SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a nostalgic yet serious cultural movement, leveraging its 2011 origin as the internet's original Bitcoin parody to capture investor attention. The community is actively highlighting its deep historical roots, recent high-profile whale endorsements, and its transition onto modern blockchain infrastructure as key factors driving its momentum.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community leans into its established two-year Solana history, using persistent meme-driven engagement and organic social promotion to rally holders. Investors are actively discussing the token's presence on the Jupiter strict list and its role within the broader meme coin meta, with discussions centered on whale accumulation and long-term community dedication.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing increased community chatter surrounding its role as a key liquidity hub on the Base ecosystem, with investors closely watching potential catalyst events and revenue growth. Community sentiment remains mixed, as some participants express frustration with current price action while others double down on accumulation strategies in anticipation of long-term utility gains.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with the community actively celebrating its early growth, developer accessibility, and airdrop events. Traders are focused on pushing the token past key market cap milestones while encouraging engagement through aggressive social media activity and strategic buying during dips.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA is experiencing a massive short squeeze following a significant uptick in trading volume and public attention related to its role in the Solana ecosystem. Community members are actively debating the token's explosive price action, with some focused on the potential for continued momentum while others caution against the volatility of this pump.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a key de-risking event for the company's heart disease gene therapy pipeline. The community is actively discussing the stock's significant short interest and the potential for a recovery toward previous highs as traders weigh clinical progress against broader macroeconomic volatility.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The TRUMP meme coin is facing severe downward pressure and community backlash, with investors reacting to allegations of a "pump and dump" scheme and frustration over the coin's utility following recent high-profile events. The conversation is dominated by intense political polarization, with critics citing the coin as part of a broader pattern of financial exploitation while supporters continue to debate its role as a speculative asset.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention driven by sustained trading volume, fueling persistent community speculation regarding a potential buyout or strategic partnership. While investors are closely monitoring clinical developments and the company's financial runway, the market remains reactive to these recurring M&A rumors despite a lack of formal announcements.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders actively accumulate during a consolidation phase, citing the project's unique "phygital" strategy and retail presence as key pillars for long-term growth. While some investors debate the risks of meme coin volatility, the community is heavily focused on potential breakout triggers and the project's ongoing brand expansion efforts.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is currently trending as investors focus on the company's central role in the nuclear energy sector, bolstered by significant federal investments in reactor buildouts and sustained long-term demand for uranium as a baseload power source for AI infrastructure. The community is actively discussing Cameco's strong institutional support and its strategic positioning within the nuclear fuel cycle while weighing the stock's recent price appreciation against long-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.</li><li>Separately, AstraZeneca announced that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of lung cancer.</li></ul>Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.Modella <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale">said</a> that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. This would allow for the generation of new insights and allow for greater automation across workflows, the company said.Shares of AZN traded marginally in the green at the time of writing.<h2 class="st-heading-2">Partnership To Acquisition</h2>Modella announced a multi-year deal with AstraZeneca in 2025 aimed at integrating its generative and agentic AI platform into AstraZeneca’s oncology research and development organization.The collaboration was aimed at supporting efforts to accelerate clinical development and enhancing biomarker discovery.<h2 class="st-heading-2">First Patient Dosing In New Late-Stage Trial</h2>Separately, AstraZeneca announced earlier on Tuesday that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of locally advanced or metastatic nonsquamous non-small cell lung cancer. Lung cancer is the most common cancer globally.Datroway, meanwhile, is a cancer drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AZN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that AstraZeneca must try to acquire smaller drugmaker Omeros Corp.<stembedurl>https://www.stocktwits.com/resq1/message/641646825</stembedurl><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 

Equity

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 


<ul class="summary-bullets"><li>MSCI, earlier had proposed to exclude crypto treasury firms from its global indexes.</li><li>MSCI said current index treatment of DATCOs identified in the preliminary list will remain unchanged.</li><li>Shares of DAT firms rallied after the announcement.&nbsp; &nbsp;</li></ul>MSCI said on Tuesday that it has decided not to implement the proposal to exclude digital asset treasury companies (DATCOs) from the MSCI Global Investable Market Indexes (MSCI Indexes) as part of the February 2026 Index Review.&nbsp;DATCOs currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said.&nbsp;However, MSCI intends to open a broader consultation on the treatment of non-operating companies in general. MSCI had earlier proposed to exclude crypto treasury firms from its global indexes. &nbsp;The consultation results were scheduled to be announced by January 15, 2026.&nbsp;Shares of one of the biggest DAT companies, Michael Saylor-backed Strategy, rallied more than 5% after the announcement. Meanwhile, Bitmine Immersion shares jumped 2.3% and Strive Asset Management shares were up 1.9% during after market hours of trading.&nbsp;MSCI said that the current index treatment of DATCOs identified in the preliminary list published by MSCI of companies whose digital asset holdings represent 50% or more of their total assets will remain unchanged.&nbsp;MSCI did flag that feedback from the consultation confirmed institutional investor concern that some DATCOs exhibit characteristics similar to investment funds, which are not eligible for inclusion in the MSCI Indexes.&nbsp;<h2 class="st-heading-2">DATs Rise</h2>Firms globally are adopting DATs to put digital currencies on their balance sheets, as interest in the sector continues to surge.&nbsp;Easing regulations around cryptocurrencies and broader acceptance of tokens for transactions has also helped several companies turn their operations into DATs or launch their subsidiaries as DATs.&nbsp;One of the biggest DAT companies is Michael Saylor-backed Strategy (MSTR), which began buying bitcoin in 2020 and has been continuing to do so ever since. Notably, the number of DAT companies has expanded over the years.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around MSTR trended in ‘extremely bullish’ territory amid ‘high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

This photo shows a smartphone screen displaying the Bitcoin cryptocurrency logo.

MSTR, BMNR, ASST Shares Rally After MSCI Decides To Not Exclude Digital Asset Treasury Firms From Its Indexes

Digital asset treasury companies currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said. 

Mag 7 Beats S&P 500 in Q3: Buy These 3 ETFs to Tap Their Strength

ETFs like XLG provide a diversified way to benefit from the Mag 7's Q3 earnings surge and the positive momentum expected going forward.

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) on Friday launched an at-home delivery service for its Flumist influenza vaccine ahead of the upcoming flu season.Flumist is a vaccine that is sprayed into the nose to help protect against influenza in people aged two through 49 years. However, it may not prevent influenza in everyone who gets vaccinated, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250815310613/en/FLUMIST-Influenza-Vaccine-Live-Intranasal-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery">stated</a>.The vaccine was initially approved by the U.S. Food and Drug Administration in 2003. It can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals aged 2-17 years.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Adults aged 18 and older can visit the Flumist website and click to order, following which they will be directed to complete a medical screening questionnaire. These submissions will then be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, to determine eligibility.Once eligibility is confirmed and insurance verified, the vaccine will be prescribed and shipped to the consumer’s home by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages.The vaccine will be delivered with clear administration instructions, storage guidance, and disposal instructions, AstraZeneca said. Once received, the vaccine should be stored in the refrigerator until use. The home delivery service will be available only in 34 states for the upcoming flu season due to local pharmacy laws, the company said. However, AstraZeneca is eyeing making the service available across all 48 contiguous states in future seasons.Flumist, meanwhile, will continue to be available in doctors’ offices and pharmacies for administration by healthcare professionals across the nation, the company added.AZN stock is up by 20% this year but down by about 8% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/big-short-investor-michael-burry-cuts-stake-in-estee-lauder/chsPoDFRdfW">‘Big Short’ Investor Michael Burry Cuts Stake In Estee Lauder By A Whopping 25% – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with placebo at 12 weeks in a late-stage study evaluating the drug in uncontrolled or treatment-resistant hypertension.Nasdaq-listed shares of the company traded 0.3% higher at the time of writing.The reduction in systolic blood pressure was both statistically significant and clinically meaningful, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html">said</a> in a statement. Baxdrostat was generally well tolerated with a favourable safety profile in the trial, where patients with uncontrolled or treatment-resistant hypertension received the investigational drug or placebo on top of standard of care.According to <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a>, there are 1.3 billion people worldwide living with hypertension, a medical condition characterised by consistently high blood pressure levels, which can, over time, damage blood vessels and vital organs. While uncontrolled hypertension persists despite treatment with two or more medications, resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.A key contributor to hypertension is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Baxdrostat is an oral, small-molecule investigational drug that inhibits an enzyme responsible for the synthesis of aldosterone in the adrenal gland.AstraZeneca acquired Baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash is payable to former CinCor shareholders upon the submission of a new drug application either in the U.S. or Europe.AstraZeneca said on Monday that the data from the late-stage trial will be shared with regulatory authorities around the world, but did not detail when it will seek approval for the drug from the U.S. Food and Drug Administration.Baxdrostat is currently being investigated in clinical trials for hypertension, primary aldosteronism, chronic kidney disease, and the prevention of heart failure in high-risk hypertensive patients.On Stocktwits, retail sentiment around AstraZeneca is unchanged within the ‘neutral’ territory over the past 24 hours, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_9_51_14_AM_png_716900ba11.webp" alt="AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>AZN stock was up by 9% this year but down by about 9% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gsk-seeks-fda-approval-for-rsv-vaccine-in-more-adults/ch8ByXHR5Vp">GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React

The reduction in systolic blood pressure in the trial was both statistically significant and clinically meaningful, the company said in a statement.

QQMG
Invesco ESG NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest QQMG News

QQMGInvesco ESG NASDAQ 100 ETF